Department of Molecular Medicine and Surgery, Section of Urology, Karolinska Institutet, Stockholm, Sweden; Academic Department of Urology, Pitié-Salpétrière Hospital, Assistance-Publique Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France.
Academic Department of Urology, Pitié-Salpétrière Hospital, Assistance-Publique Hôpitaux de Paris, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France.
Eur Urol Focus. 2020 Mar 15;6(2):327-338. doi: 10.1016/j.euf.2018.10.009. Epub 2018 Oct 30.
The use of the artificial urinary sphincter (AUS) for female non-neurogenic severe stress urinary incontinence (SUI) due to sphincter deficiency is either not specifically registered and/or reimbursed in some countries worldwide, as opposed to males, in whom it is considered the gold standard. With waning popularity of synthetic midurethral slings for the treatment of SUI, evidence-based assessment of AUS performance and safety is mandatory for patient counselling.
To conduct a systematic review of studies evaluating short- to long-term AUS performance and safety outcomes in non-neurogenic adult females with severe SUI.
PubMed/Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched, from 1987 to 2018, without language restriction. Included studies had to report outcomes after AUS implantation in at least five adult women with non-neurogenic SUI, after a minimum follow-up of 6 months.
Twelve articles collecting data from 886 patients were identified, no study being randomised or prospective. The reported zero pad rates ranged from 42% to 86%, revision rates from 6% to 44%, and mechanical failure rates from 2% to 41%. Procedure serious adverse event rates ranged from 2% to 54% and rates of serious adverse device effects such as explantation ranged from 2% to 27%.
The level of evidence supporting the use of an AUS for non-neurogenic SUI in women is very low. AUS outcome assessments necessitate well-designed randomised trials, in accordance with current evidence-based medicine requirements.
In this article, reviewing the scientific literature over the last 30 yr, we looked at the short- to long-term efficacy and safety of the artificial urinary sphincter in adult women for the treatment of severe urine leakage. We conclude that the data analysed provide very low evidence and that further well-conducted trials with large populations are required.
在世界范围内,由于缺乏括约肌,一些国家并未专门登记和/或报销女性非神经源性严重压力性尿失禁(SUI)患者使用人工尿道括约肌(AUS),而男性患者则将其视为金标准。随着合成型尿道中段吊带治疗 SUI 的普及度降低,有必要基于循证医学对 AUS 的疗效和安全性进行评估,为患者提供咨询。
对非神经源性成年女性严重 SUI 患者使用 AUS 的短期至长期疗效和安全性进行系统评价。
从 1987 年到 2018 年,在PubMed/Medline、Embase 和 Cochrane 对照试验中心注册库中,无语言限制地进行了检索。纳入的研究必须报告至少 5 例非神经源性 SUI 成年女性在接受 AUS 植入后 6 个月以上的结果。
共确定了 12 篇文章,这些文章共纳入了 886 例患者的数据,没有研究为随机或前瞻性研究。报告的零垫率为 42%至 86%,翻修率为 6%至 44%,机械故障率为 2%至 41%。手术严重不良事件发生率为 2%至 54%,严重不良器械相关事件(如植入物取出)发生率为 2%至 27%。
支持女性非神经源性 SUI 使用 AUS 的证据水平非常低。AUS 结果评估需要按照当前循证医学的要求进行精心设计的随机试验。
在本文中,我们回顾了过去 30 年来的科学文献,研究了人工尿道括约肌在治疗成年女性严重尿失禁中的短期至长期疗效和安全性。我们的结论是,分析的数据提供的证据非常有限,需要进行进一步的、有大样本量的良好设计的试验。